November 2024 Supplement - Endovascular Today
News and information on minimally invasive vascular disease therapies, covering peripheral vascular disease, aneurysms, stroke, hypertension, dialysis access, and venous issues.
November 2024 Supplement - Endovascular Today
Embracing a New Era: Putting Data Into Practice. Dr. Silver moderates a panel of experts who discuss their experiences with the Neuroguard IEP® System, insights into the data, device design characteristics, and impact on the field.
Bentley’s BeGraft and BeFlared Gain TÜV Certification as Bridging ...
November 20, 2024—Bentley InnoMed GmbH announced it has been granted two TÜV certificates that extend indications for its stents in complex
November 2024 Issue - Endovascular Today
Initiatives to Improve Awareness of Aortic Dissection. Advocates with Aortic Hope/Think Aorta, The John Ritter Foundation for Aortic Health, and The Aortic Dissection Collaborative for Patient-Centered Research discuss how they are raising awareness of aortic …
Xeltis Receives FDA Breakthrough Device Designation for aXess …
November 19, 2024—Xeltis recently announced that the FDA has granted Breakthrough Device designation for the company’s aXess vascular access conduit and that the first patient was enrolled in the aXess staged pivotal trial in the United States.. The aXess device is intended to enable the creation of a new, permanent, living vessel for …
Introduction - Endovascular Today
This focused supplement to Endovascular Today comes on the heels of the recent FDA approval of the Neuroguard IEP® System, a 3-in-1 carotid stent + dilation balloon + Integrated Embolic Protection (IEP) system (Contego Medical). This FDA approval is supported by unprecedented safety outcomes from the PERFORMANCE I and II trials, which will be reviewed herein.
Endovascular Today
Biotronik’s BIO-OSCAR FIRST Trial Begins Enrollment. December 19, 2024—Biotronik announced the enrollment of the first patients in its BIO-OSCAR FIRST trial, which is designed to confirm the safety and clinical performance of the company’s Oscar peripheral multifunctional catheter for dilation of lesions in the femoral, popliteal, and …
Synchron’s Brain-Computer Interface Evaluated in COMMAND …
October 3, 2024—Synchron recently announced positive results from the COMMAND early feasibility study, which is evaluating the safety and efficacy of the Synchron brain computer interface (BCI, called the Stentrode) in six patients over a 12-month period.. The results were presented by the COMMAND study Coprincipal Investigator Elad Levy, MD, at the 2024 Congress of Neurological Surgeons ...
1-Year Data Presented From enVVeno’s VenoValve Pivotal Trial
November 20, 2024—enVVeno Medical Corporation announced 1-year data on all patients from SAVVE, the United States pivotal trial of the company’s VenoValve, a surgical replacement venous valve being developed for the treatment of deep venous chronic venous insufficiency (CVI).. The findings were presented at the 51st annual VEITHsymposium held November 19-23, 2024, in New York, New York.
Thoracic Aortic Aneurysms: At What Size Should We Intervene?
Thoracic aortic aneurysm (TAA) is a potentially life-threatening disorder that without intervention carries a poor prognosis. Once diagnosed, the 3-year survival for large degenerative TAAs (> 60 mm in diameter) is approximately 20%. 1 Hospital admissions in the United Kingdom for TAAs have doubled in the last decade, and von Allmen and colleagues reported a TAA hospital admission rate of nine ...